Literature DB >> 9894872

Effects of PMP22 duplication and deletions on the axonal cytoskeleton.

Z Sahenk1, L Chen, J R Mendell.   

Abstract

Axonal loss in Charcot-Marie-Tooth type 1A (CMT1A) is an important feature correlated with the functional disability in affected individuals. It is not known, however, how the most common genetic defect in Schwann cells (PMP22 duplication) causes the CMT1A phenotype and results in axonal loss. In this study, sural nerve segments from individuals with PMP22 duplications or deletions, causing the reciprocal disorder hereditary neuropathy with pressure palsies (HNPP), were grafted into the cut ends of the sciatic nerve of nude mice. The xenografts and host segments were studied at 2, 4, 6, 8, 12, and 16 weeks after grafting and compared with the controls from healthy volunteers. Within the CMT1A xenografts, the nude mice axons in the proximal part of the graft showed a significant increase in axonal area with an increase in the neurofilament and membranous organelle (mitochondria) density, compared with distal graft and distal host segments. A preferential distal axonal loss, associated with a perpetual axonal atrophy, degeneration, and axonal sprouting was observed over time, with increasing intensity at 8 to 16 weeks. These alterations were seen to a lesser extent in HNPP xenografts and were not observed in controls. In addition, the onset of regeneration-associated myelination was delayed, more significantly in HNPP xenografts than those of CMT1A. Our findings indicate that the PMP22 duplication in Schwann cells results in an impairment in the normal axonal cytoskeletal organization, resulting in distal axonal degeneration and fiber loss, and the affect of PMP22 deletion on axonal cytoskeleton is less deleterious.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9894872     DOI: 10.1002/1531-8249(199901)45:1<16::aid-art5>3.0.co;2-f

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

1.  A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.

Authors:  I V Mersiyanova; A V Perepelov; A V Polyakov; V F Sitnikov; E L Dadali; R B Oparin; A N Petrin; O V Evgrafov
Journal:  Am J Hum Genet       Date:  2000-06-07       Impact factor: 11.025

Review 2.  Myelin disorders: Causes and perspectives of Charcot-Marie-Tooth neuropathy.

Authors:  Gerd Meyer zu Hörste; Thomas Prukop; Klaus-Armin Nave; Michael W Sereda
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

3.  Axonal pathology precedes demyelination in a mouse model of X-linked demyelinating/type I Charcot-Marie Tooth neuropathy.

Authors:  Natalie Vavlitou; Irene Sargiannidou; Kyriaki Markoullis; Kyriacos Kyriacou; Steven S Scherer; Kleopas A Kleopa
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

Review 4.  Schwann cells as a therapeutic target for peripheral neuropathies.

Authors:  Helmar C Lehmann; Ahmet Höke
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-12       Impact factor: 4.388

5.  Determinants of reduced health-related quality of life in pediatric inherited neuropathies.

Authors:  J Burns; S Ramchandren; M M Ryan; M Shy; R A Ouvrier
Journal:  Neurology       Date:  2010-08-24       Impact factor: 9.910

6.  Axonal Charcot-Marie-Tooth disease and the neurofilament light gene (NF-L)

Authors:  J R Lupski
Journal:  Am J Hum Genet       Date:  2000-06-07       Impact factor: 11.025

7.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 8.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

Review 9.  Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease?

Authors:  Marcel Maier; Philipp Berger; Ueli Suter
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

Review 10.  Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A.

Authors:  A M Robertson; J Perea; A McGuigan; R H M King; J R Muddle; A A Gabreëls-Festen; P K Thomas; C Huxley
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.